Hengrui Pharma's Novel Drug SHR-1918 Injection Receives Marketing Application Acceptance and Priority Review Status

Hengrui Pharma's Innovative Drug HRS-5346 for Elevated Lipoprotein(a) Levels Added to Breakthrough Therapy List

Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug

HENGRUI PHARMA's New Antibody Drug Application for Injectable SHR-A1811 Accepted and Granted Priority Review

BRIEF-Kailera Therapeutics & Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral Ribupatide

Kailera, Hengrui's experimental pill shows 12.1% weight loss in mid-stage trial

Kailera Therapeutics: Mean Weight Loss of up to 12.1% With No Observed Plateau at 26 Weeks in Phase 2 Trial in China With Oral Ribupatide

Hengrui Pharma's HRS-4642 Injection Granted Breakthrough Therapy Designation

HENGRUI PHARMA (01276) Allocates 9.317 Million Yuan for 165,000 A-Share Buyback on February 4

Hengrui Pharma: Resubmitted Camrelizumab Injection Combination Therapy Application Accepted by FDA

Hengrui Pharma (600276.SH) Resubmits BLA for Camrelizumab Injection, Accepted by FDA

HENGRUI PHARMA (01276): Marketing Authorization Application for HR20013 Injection Accepted by NMPA

Valuation Ranges of Biopharma: Insights from Innovent Biologics, Hengrui Pharmaceuticals, and BeiGene

Zhixintong A-H Statistics | January 30th

Hengrui Pharma (01276) Receives Clinical Trial Approval for HRS-7535 Tablets

HENGRUI PHARMA (01276) Marketing Application for New Indication of Innovative Drug Camrelizumab and Apatinib Combination Accepted

Hengrui Pharma (01276) Repurchases 371,600 A-Shares for RMB 21.074 Million on January 29

Hengrui Pharma (01276) Completes Cumulative Share Buyback of 9.0737 Million Shares by January 27

HENGRUI PHARMA (01276): SHR-1049 Injection Receives Drug Clinical Trial Approval Notice